Lead Product(s) : BX001
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting
Details : BiomX is developing BX001, a topically administered gel comprised of a cocktail of naturally occurring phage targeting Cutibacterium acnes (C. acnes) used to modify the appearance of acne prone skin.
Product Name : BX001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2020
Lead Product(s) : BX001
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable